KEMPENI, JOACHIM,WEISS, ROBERTA,FISCHKOFF, STEVEN, A.
申请号:
HK04107891.1
公开号:
HK1065471B
申请日:
2004.10.13
申请国别(地区):
HK
年份:
2013
代理人:
摘要:
Methods of treating disorders in which TNF± activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ± (hTNF ±) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF± (e.g., K d = 10 -8 M or less), a slow off rate for hTNF± dissociation (e.g., K off = 10 -3 sec -1 or less) and neutralize hTNF± activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.